Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies
Genentech is terminating its cell therapy collaboration with Adaptive Biotechnologies, a deal originally valued at up to $2 billion and launched in January 2019 to develop personalized cancer treatments using T-cell receptor technology.
The partnership leveraged Adaptive's TruTCR platform to profile immune responses and aimed to create individual therapies based on each patient's cancer-specific antigens.
The cancellation will be final on February 9, 2026, as reported in an August 18, 2025 SEC filing, and is part of Genentech's recent broader efforts around cost-cutting and downsizing.
Adaptive received $300 million upfront in the original deal, with the remaining value tied to milestones that will now no longer be pursued.
Both companies noted the decision was not due to emerging safety concerns but was made after careful consideration; Adaptive announced it will continue advancing its TCR discovery model and pursue other partnerships and immunology applications, including work in autoimmunity.